CR10555A - Vacunas para malaria - Google Patents

Vacunas para malaria

Info

Publication number
CR10555A
CR10555A CR10555A CR10555A CR10555A CR 10555 A CR10555 A CR 10555A CR 10555 A CR10555 A CR 10555A CR 10555 A CR10555 A CR 10555A CR 10555 A CR10555 A CR 10555A
Authority
CR
Costa Rica
Prior art keywords
protein
vivax
malaria
vaccines
monoclonal
Prior art date
Application number
CR10555A
Other languages
English (en)
Inventor
D Cohen Joseph
Marchand Martine
F Ockenhouse Christian
Yadava Anjali
Original Assignee
Glaxosmithkline Biolog Sa
Us Army
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB0614254.1A external-priority patent/GB0614254D0/en
Priority claimed from GB0614473A external-priority patent/GB0614473D0/en
Priority claimed from GB0614476A external-priority patent/GB0614476D0/en
Priority claimed from GB0615115A external-priority patent/GB0615115D0/en
Application filed by Glaxosmithkline Biolog Sa, Us Army filed Critical Glaxosmithkline Biolog Sa
Publication of CR10555A publication Critical patent/CR10555A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/002—Protozoa antigens
    • A61K39/015—Hemosporidia antigens, e.g. Plasmodium antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/29—Hepatitis virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • A61P33/06—Antimalarials
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/44—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from protozoa
    • C07K14/445—Plasmodium
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6075—Viral proteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Abstract

La presente invencion se refiere a una proteina novedosa hibrida/ de fusion derivada de la proteina CS de Plasmodium vivax (P. vivax), los procedimientos para preparar y purificar la misma, su uso en medicina, particularmente en la prevencion de infecciones de malaria, por ejemplo las provocadas por P. vivax, las composiciones/vacunas que contienen la proteina o anticuerpos contra la proteina tales como anticuerpos monoclonales o policionales y uso de los mismos, particularmente en terapia.
CR10555A 2006-07-18 2009-01-14 Vacunas para malaria CR10555A (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GBGB0614254.1A GB0614254D0 (en) 2006-07-18 2006-07-18 Vaccine
GB0614473A GB0614473D0 (en) 2006-07-20 2006-07-20 Vaccines
GB0614476A GB0614476D0 (en) 2006-07-20 2006-07-20 Vaccine
GB0615115A GB0615115D0 (en) 2006-07-28 2006-07-28 Vaccines

Publications (1)

Publication Number Publication Date
CR10555A true CR10555A (es) 2009-04-29

Family

ID=38957130

Family Applications (2)

Application Number Title Priority Date Filing Date
CR10555A CR10555A (es) 2006-07-18 2009-01-14 Vacunas para malaria
CR10561A CR10561A (es) 2006-07-18 2009-01-14 Vacunas para malaria

Family Applications After (1)

Application Number Title Priority Date Filing Date
CR10561A CR10561A (es) 2006-07-18 2009-01-14 Vacunas para malaria

Country Status (22)

Country Link
US (2) US9592282B2 (es)
EP (2) EP2040742B1 (es)
JP (2) JP5592110B2 (es)
KR (2) KR20090092752A (es)
AR (1) AR061894A1 (es)
AU (2) AU2007276219B2 (es)
BR (2) BRPI0714326A2 (es)
CA (2) CA2657353A1 (es)
CO (2) CO6150189A2 (es)
CR (2) CR10555A (es)
EA (2) EA200900033A1 (es)
ES (2) ES2437082T3 (es)
IL (2) IL196410A0 (es)
MA (2) MA30670B1 (es)
MX (2) MX2009000655A (es)
NO (2) NO20090177L (es)
NZ (2) NZ574238A (es)
PE (1) PE20080428A1 (es)
SG (2) SG173377A1 (es)
TW (1) TW200819462A (es)
WO (2) WO2008009650A2 (es)
ZA (1) ZA200900386B (es)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040136963A1 (en) * 2001-06-22 2004-07-15 The Trustees Of The University Of Pennsylvania Simian adenovirus vectors and methods of use
EP1453543B1 (en) 2001-11-21 2017-08-30 The Trustees Of The University Of Pennsylvania Simian adenovirus nucleic acid and amino acid sequences, vectors containing same, and methods of use
SG173377A1 (en) * 2006-07-18 2011-08-29 Glaxosmithkline Biolog Sa Vaccines for malaria
TW200938633A (en) * 2007-12-06 2009-09-16 Glaxosmithkline Biolog Sa Vaccine
PE20091529A1 (es) * 2007-12-24 2009-10-29 Glaxosmithkline Biolog Sa Vacunas contra la malaria
BRPI0919245A2 (pt) * 2008-09-24 2021-11-03 Us Gov Sec Army Vacina para malária
US10041049B2 (en) * 2008-11-03 2018-08-07 Janssen Vaccines & Prevention B.V. Method for the production of adenoviral vectors
US8784832B2 (en) 2011-08-19 2014-07-22 University Of South Florida (A Florida Non-Profit Corporation) Synthetic antigen based on the ligand domain of the Plasmodium vivax duffy binding protein
GB201116248D0 (en) * 2011-09-20 2011-11-02 Glaxosmithkline Biolog Sa Liposome production using isopropanol
US9580482B2 (en) 2012-02-17 2017-02-28 Children's Medical Center Corporation Conformation-stabilized TRAP antigens
US9821046B2 (en) 2013-01-21 2017-11-21 Oxford University Innovation Limited Composition and uses thereof
EP3213638A1 (en) 2016-03-01 2017-09-06 Coöperatie Avebe U.A. Vegan cheese analogue
GB201608821D0 (en) 2016-05-19 2016-07-06 Isis Innovation Vaccines
CN110035770B (zh) 2016-12-07 2023-06-16 葛兰素史密丝克莱恩生物有限公司 新方法
AU2017393085B2 (en) * 2016-12-23 2024-02-29 The Walter And Eliza Hall Institute Of Medical Research System, method, apparatus and diagnostic test for Plasmodium vivax
WO2022059089A1 (ja) 2020-09-16 2022-03-24 三菱電機株式会社 前照灯装置

Family Cites Families (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4235877A (en) 1979-06-27 1980-11-25 Merck & Co., Inc. Liposome particle containing viral or bacterial antigenic subunit
SE8205892D0 (sv) 1982-10-18 1982-10-18 Bror Morein Immunogent membranproteinkomplex, sett for framstellning och anvendning derav som immunstimulerande medel och sasom vaccin
US4826957A (en) * 1985-07-12 1989-05-02 New York University Immunogenic recombinant yeast expression product and method for purifying it
DE3650242T2 (de) * 1985-07-12 1995-06-14 Univ New York Mit dem plasmodium-vivax-circumsporozoit-protein übereinstimmendes immunogenes peptidantigen.
US5554372A (en) 1986-09-22 1996-09-10 Emory University Methods and vaccines comprising surface-active copolymers
JPH0222300A (ja) * 1987-02-02 1990-01-25 Swiss Serum & Vaccine Inst Bern 免疫原性接合体およびその製法ならびに免疫を生ぜしめる方法
US4997647A (en) * 1987-03-30 1991-03-05 New York University Vaccine against the sporozoite stage of malaria
EP0362278A4 (en) 1987-06-05 1990-05-14 Us Health FACTORS OF AUTOCRINE MOTILITY IN THE DIAGNOSIS AND TREATMENT OF CANCER.
US5278302A (en) 1988-05-26 1994-01-11 University Patents, Inc. Polynucleotide phosphorodithioates
US4912094B1 (en) 1988-06-29 1994-02-15 Ribi Immunochem Research Inc. Modified lipopolysaccharides and process of preparation
US4977647A (en) * 1989-10-27 1990-12-18 D.B. Industries, Inc. Double locking snap hook
EP0468520A3 (en) 1990-07-27 1992-07-01 Mitsui Toatsu Chemicals, Inc. Immunostimulatory remedies containing palindromic dna sequences
DK0614465T3 (da) 1991-11-16 1999-09-27 Smithkline Beecham Biolog Hybridprotein mellem CS fra Plasmodium og HBsAg
RU2118164C1 (ru) 1992-06-25 1998-08-27 Смитклайн Бичам Байолоджикалс, С.А. Вакцинная композиция, обладающая свойством вызывать цитолитический т-клеточный ответ у млекопитающих, способ получения цитолитического т-клеточного ответа in vivo, способ получения вакцины
AU685443B2 (en) 1993-03-23 1998-01-22 Smithkline Beecham Biologicals (Sa) Vaccine compositions containing 3-O deacylated monophosphoryl lipid A
JPH09502353A (ja) 1993-09-10 1997-03-11 アメリカ合衆国 プラスモジウム・ビバックスおよびプラスモジウム・ファルシパルム赤血球結合蛋白質からの結合領域
AU700485B2 (en) 1993-11-17 1999-01-07 Om Pharma Glucosamine disaccharides, method for their preparation, pharmaceutical composition comprising same, and their use
GB9326253D0 (en) 1993-12-23 1994-02-23 Smithkline Beecham Biolog Vaccines
WO1995026204A1 (en) 1994-03-25 1995-10-05 Isis Pharmaceuticals, Inc. Immune stimulation by phosphorothioate oligonucleotide analogs
GB9620795D0 (en) 1996-10-05 1996-11-20 Smithkline Beecham Plc Vaccines
UA56132C2 (uk) 1995-04-25 2003-05-15 Смітклайн Бічем Байолоджікалс С.А. Композиція вакцини (варіанти), спосіб стабілізації qs21 відносно гідролізу (варіанти), спосіб приготування композиції вакцини
US5666153A (en) 1995-10-03 1997-09-09 Virtual Shopping, Inc. Retractable teleconferencing apparatus
US20030133944A1 (en) * 2001-04-05 2003-07-17 Smithkline Beecham Biologicals S.A. Vaccine composition against malaria
GB9616351D0 (en) * 1996-08-02 1996-09-11 Smithkline Beecham Biolog Vaccine composition
US6083716A (en) 1996-09-06 2000-07-04 The Trustees Of The University Of Pennsylvania Chimpanzee adenovirus vectors
US6303347B1 (en) 1997-05-08 2001-10-16 Corixa Corporation Aminoalkyl glucosaminide phosphate compounds and their use as adjuvants and immunoeffectors
US6764840B2 (en) 1997-05-08 2004-07-20 Corixa Corporation Aminoalkyl glucosaminide phosphate compounds and their use as adjuvants and immunoeffectors
US6113918A (en) 1997-05-08 2000-09-05 Ribi Immunochem Research, Inc. Aminoalkyl glucosamine phosphate compounds and their use as adjuvants and immunoeffectors
GB9711990D0 (en) 1997-06-11 1997-08-06 Smithkline Beecham Biolog Vaccine
KR100766016B1 (ko) 1998-06-30 2007-10-11 옴 파르마 아실 유사디펩티드, 이의 제조 방법 및 이를 함유하는 약제 조성물
KR20000020497A (ko) 1998-09-21 2000-04-15 임채승 말라리아의 검출방법
US6558670B1 (en) 1999-04-19 2003-05-06 Smithkline Beechman Biologicals S.A. Vaccine adjuvants
KR100922031B1 (ko) 1999-04-19 2009-10-19 글락소스미스클라인 바이오로지칼즈 에스.에이. 백신
AU1600401A (en) 1999-11-12 2001-06-06 Chinese University Of Hong Kong, The Malaria vaccine
WO2001046127A1 (fr) 1999-12-22 2001-06-28 Om Pharma Pseudodipeptides acyles porteurs d'un bras auxiliaire fonctionnalise
GB0027088D0 (en) 2000-11-06 2000-12-20 Glaxo Group Ltd DNA expression vectors
US6942866B2 (en) 2000-08-16 2005-09-13 Apovia, Inc. Malaria immunogen and vaccine
EP1201250A1 (en) 2000-10-25 2002-05-02 SMITHKLINE BEECHAM BIOLOGICALS s.a. Immunogenic compositions comprising liver stage malarial antigens
MXPA04000024A (es) 2001-06-22 2004-05-21 Univ Pennsylvania Metodos para inducir una respuesta inmunologica citotoxica y composiciones de adenovirus simio recombinante utiles en los mismos.
RU2356577C9 (ru) 2002-10-23 2009-08-10 Глаксосмитклайн Байолоджикалс С.А. Способы вакцинации против малярии
CA2507915C (en) 2002-12-17 2013-07-02 Crucell Holland B.V. Recombinant viral-based malaria vaccines
ES2478625T3 (es) 2003-06-20 2014-07-22 The Trustees Of The University Of Pennsylvania Método de generación de adenovirus quiméricos y usos de tales adenovirus quiméricos
ES2385481T3 (es) 2003-06-20 2012-07-25 Siemens Healthcare Diagnostics Products Gmbh Nueva variante de proteína de superficie (HbsAg) del virus de hepatitis B
US20050233435A1 (en) 2003-09-04 2005-10-20 Nyu Medical Center Plasmodium axenic liver stages as a noninfectious whole organism malaria vaccine
GB0321615D0 (en) 2003-09-15 2003-10-15 Glaxo Group Ltd Improvements in vaccination
US20060041248A1 (en) * 2004-08-23 2006-02-23 Patton David L Pharmaceutical compositions delivery system and methods
GB0420634D0 (en) 2004-09-16 2004-10-20 Glaxosmithkline Biolog Sa Vaccines
WO2006088597A2 (en) * 2005-01-18 2006-08-24 Walter Read Army Institute Of Research A plasmodium vivax hybrid circumsporozoite protein and vaccine
GB0513421D0 (en) 2005-06-30 2005-08-03 Glaxosmithkline Biolog Sa Vaccines
SG173377A1 (en) * 2006-07-18 2011-08-29 Glaxosmithkline Biolog Sa Vaccines for malaria
PE20091529A1 (es) * 2007-12-24 2009-10-29 Glaxosmithkline Biolog Sa Vacunas contra la malaria

Also Published As

Publication number Publication date
EA200900032A1 (ru) 2011-02-28
SG173377A1 (en) 2011-08-29
WO2008009652A3 (en) 2008-05-08
ES2437082T3 (es) 2014-01-08
NZ574239A (en) 2011-12-22
MX2009000650A (es) 2009-07-02
CA2657279A1 (en) 2008-01-24
US9592282B2 (en) 2017-03-14
BRPI0715581A2 (pt) 2013-04-24
MA30671B1 (fr) 2009-08-03
SG173363A1 (en) 2011-08-29
CO6150189A2 (es) 2010-04-20
NO20090177L (no) 2009-02-16
AU2007276217B2 (en) 2013-08-29
IL196410A0 (en) 2011-08-01
NZ574238A (en) 2012-02-24
AU2007276217A1 (en) 2008-01-24
BRPI0714326A2 (pt) 2013-05-07
KR20090092752A (ko) 2009-09-01
MA30670B1 (fr) 2009-08-03
US9364525B2 (en) 2016-06-14
PE20080428A1 (es) 2008-05-15
WO2008009652A2 (en) 2008-01-24
EP2040743B1 (en) 2013-10-02
JP5222289B2 (ja) 2013-06-26
JP2009543569A (ja) 2009-12-10
CR10561A (es) 2009-04-29
NO20090178L (no) 2009-02-09
AU2007276219A1 (en) 2008-01-24
CA2657353A1 (en) 2008-01-24
WO2008009650A2 (en) 2008-01-24
TW200819462A (en) 2008-05-01
CO6150187A2 (es) 2010-04-20
JP5592110B2 (ja) 2014-09-17
AU2007276217A8 (en) 2009-02-26
AR061894A1 (es) 2008-10-01
EP2040742B1 (en) 2014-10-29
MX2009000655A (es) 2009-07-02
EA200900033A1 (ru) 2009-12-30
WO2008009650A3 (en) 2008-04-10
IL196471A0 (en) 2011-08-01
EP2040743A2 (en) 2009-04-01
US20100150998A1 (en) 2010-06-17
ZA200900386B (en) 2014-03-26
AU2007276219B2 (en) 2013-10-03
EP2040742A2 (en) 2009-04-01
KR20090094213A (ko) 2009-09-04
ES2525732T3 (es) 2014-12-29
US20100062028A1 (en) 2010-03-11
JP2009543846A (ja) 2009-12-10

Similar Documents

Publication Publication Date Title
CR10555A (es) Vacunas para malaria
CR20150625A (es) Composición que comprende anticuerpo que se fija al dominio ii de her2 y sus variantes acidas
CY1117563T1 (el) Αντισωματα κατα her3 και χρησεις αυτων
CL2016002816A1 (es) Anticuerpos anti-cd 134 (ox40) y usos de los mismos (divisional de sol. n° 631-14).
CY1117331T1 (el) Αντισωματα προσδεσης στην εξωκυτταρικη περιοχη 4 του ανθρωπινου csf1r και η χρηση αυτων
CY1115091T1 (el) Διειδικες πρωτεϊνες προσδεσης αντιγονων
MX2009005414A (es) Formulaciones liquidas de anticuerpo antirrabico.
GT201400049A (es) "anticuerpos a pcsk9 y usos de los mismo"
CO6491045A2 (es) Composiciones de proteina f de virus sincitial respiratorio (rsv) y metodos para producir las mismas
EA200970247A1 (ru) Способ получения оптического активного n-защищенного 3-аминопирролидина или оптически активного n-защищенного 3-аминопиперидина и соответствующих кетонов путем оптического разделения рацемических смесей аминов с использованием бактериальной омега-трансаминазы
MX336682B (es) Anticuerpos contra csf-1r humanos y usos de los mismos.
ECSP088778A (es) Formulacion de un anticuerpo monoclonal humano anti-igf-1r
BR112014012275A2 (pt) purificação de proteína com a utilização de tampão bis-tris
EA201170396A1 (ru) 2-оксо-1,2-дигидрохинолиновые модуляторы иммунной функции
EA201001680A1 (ru) Соединения бензолсульфонамидтиазола и оксазола
AR088920A1 (es) Purificacion de anticuerpos anti-c-met
MA35009B1 (fr) Cristaux d'anticorps anti-sclérotine et formulations de ceux-ci
SG178886A1 (en) Humanized anti-cdcp1 antibodies
ATE552276T1 (de) Modifizierter anti-cd52-antikörper
UA113623C2 (uk) Моноклональне антитіло проти інгібітору шляху тканинного фактора (tfpi)
CR11307A (es) Vacunas
EA201390467A1 (ru) Композиции антител и способы применения
WO2012047267A3 (en) Polyvalent immunogen
EA200800601A1 (ru) Связывающие fas антитела
ECSP13012481A (es) Composiciones de anticuerpo anti-vegfr-3

Legal Events

Date Code Title Description
FA Abandonment or withdrawal (granting procedure)